Cargando…
Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
BACKGROUND: Although immunotherapy greatly extends overall survival (OS) of patients with extensive-stage small cell lung cancer (ES-SCLC), a number of patients develop immunotherapy resistance (IR). Patterns of failure in ES-SCLC are not clarified. Our study aims to explore the clinical pattern of...
Autores principales: | Liu, Li, Liu, Tong, Wang, Xingwen, Wang, Jianbo, Wang, Jun, Yuan, Meng, Yang, Yunxin, Zhang, Yingying, Wang, Hang, Hu, Pingping, Zhang, Jiandong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206491/ https://www.ncbi.nlm.nih.gov/pubmed/37182510 http://dx.doi.org/10.1016/j.tranon.2023.101687 |
Ejemplares similares
-
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
por: Zhang, Tengfei, et al.
Publicado: (2016) -
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019) -
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016) -
PD-L1 Status in Refractory Lymphomas
por: Vranic, Semir, et al.
Publicado: (2016) -
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)